Bernstein raised the firm’s price target on Sarepta (SRPT) to $20 from $18 and keeps a Market Perform rating on the shares. The firm cites higher estimates for Elevidys, partially offset by a slightly lower multiple reflecting greater uncertainty on PMO durability post-ESSENCE.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta provides update on SRP-1003 study
- Arrowhead earns $200M milestone payment from Sarepta
- Citizens JMP healthcare analysts hold an analyst/industry conference
- New Sarepta label weakens commercial narrative, says H.C. Wainwright
- Cautious Hold Rating on Sarepta Therapeutics Amid Elevidys Label Updates and Safety Concerns